GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IDEXX Laboratories Inc (MEX:IDXX) » Definitions » Revenue

IDEXX Laboratories (MEX:IDXX) Revenue : MXN68,899 Mil (TTM As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is IDEXX Laboratories Revenue?

IDEXX Laboratories's revenue for the three months ended in Sep. 2024 was MXN19,209 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2024 was MXN68,899 Mil. IDEXX Laboratories's Revenue per Share for the three months ended in Sep. 2024 was MXN231.27. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was MXN824.64.

Good Sign:

IDEXX Laboratories Inc has shown predictable revenue and earnings growth.

During the past 12 months, the average Revenue per Share Growth Rate of IDEXX Laboratories was 7.60% per year. During the past 3 years, the average Revenue per Share Growth Rate was 11.80% per year. During the past 5 years, the average Revenue per Share Growth Rate was 12.30% per year. During the past 10 years, the average Revenue per Share Growth Rate was 13.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, IDEXX Laboratories's highest 3-Year average Revenue per Share Growth Rate was 35.60% per year. The lowest was 8.40% per year. And the median was 13.45% per year.


IDEXX Laboratories Revenue Historical Data

The historical data trend for IDEXX Laboratories's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDEXX Laboratories Revenue Chart

IDEXX Laboratories Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45,394.29 53,840.78 65,959.90 65,649.35 62,141.92

IDEXX Laboratories Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15,947.47 15,304.00 16,000.37 18,385.65 19,208.73

Competitive Comparison of IDEXX Laboratories's Revenue

For the Diagnostics & Research subindustry, IDEXX Laboratories's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IDEXX Laboratories's Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's Revenue distribution charts can be found below:

* The bar in red indicates where IDEXX Laboratories's Revenue falls into.



IDEXX Laboratories Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN68,899 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IDEXX Laboratories  (MEX:IDXX) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


IDEXX Laboratories Revenue Related Terms

Thank you for viewing the detailed overview of IDEXX Laboratories's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


IDEXX Laboratories Business Description

Address
One IDEXX Drive, Westbrook, ME, USA, 04092
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.